目的 研究腎復(fù)康膠囊聯(lián)合他克莫司膠囊治療膜性腎病的臨床療效。方法 選取2017年10月—2019年10月在河南科技大學(xué)第一附屬醫(yī)院治療的84例膜性腎病患者，所有患者隨機分為對照組和治療組，每組各42例。對照組餐前1 h口服他克莫司膠囊，0.05 mg/（kg·d），2次/d；治療組在對照組基礎(chǔ)上口服腎復(fù)康膠囊，4粒/次，3次/d。兩組患者持續(xù)治療4周。觀察兩組的臨床療效，比較兩組的腎功能指標(biāo)、炎性因子水平。結(jié)果 治療后，對照組和治療組的總有效率分別為80.95%、95.24%，兩組比較差異有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組患者24 h尿蛋白（24 h UTP）、血肌酐（Scr）和血尿素氮（BUN）水平顯著降低（P<0.05）；并且治療組腎功能指標(biāo)明顯低于對照組（P<0.05）。治療后，兩組患者白細胞介素-4（IL-4）、白細胞介素-10（IL-10）水平均顯著降低（P<0.05）；且治療組血清炎性因子水平顯著低于對照組（P<0.05）。結(jié)論 腎復(fù)康膠囊聯(lián)合他克莫司膠囊治療膜性腎病具有較好的治療效果，能夠改善患者腎功能，降低血清炎性因子水平，安全性較高，值得在臨床上推廣應(yīng)用。

Objective To study the clinical effect of Shenfukang Capsules combined with Tacrolimus Capsules in treatment of membranous nephropathy. Methods Patients (84 cases) with membranous nephropathy in the First Affiliated Hospital of Henan University of Science and Technology from October 2017 to October 2019 were randomly divided into control and treatment groups, and each group had 42 cases. Patients in the control group were po administered with Tacrolimus Capsules at 1 h before meals, 0.05 mg/(kg·d), twice daily. Patients in the treatment group were po administered with Shenfukang Capsules on the basis of the control group, 4 grains/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacies were evaluated, and renal function and inflammatory factors in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 80.95% and 95.24%, respectively, and there was difference between two groups (P<0.05). After treatment, the levels of 24 h UTP, Scr and BUN in two groups were significantly decreased (P<0.05). And the renal function indexes in the treatment group were significantly lower than those in the control group (P<0.05). After treatment, the levels of IL-4 and IL-10 in two groups were significantly decreased (P<0.05). And the inflammatory factors in the treatment group were significantly lower than those in the control group (P<0.05). Conclusion Shenfukang Capsules combined with Tacrolimus Capsules has clinical curative effect in treatment of membranous nephropathy, can improve the renal function of patients, reduce the serum level of inflammatory factors, with good safety, which is worthy of clinical application.

R976